Breast Milk Sugar Boosts Good Gut Bacteria and Metabolism in Older Adults
A 6-week RCT shows 2′-fucosyllactose raises Bifidobacterium, HDL, insulin, and FGF21 in adults over 60, with cognitive benefits in responders.
Summary
Researchers at Stanford ran a 6-week randomized controlled trial giving 89 adults (mean age 67) either 1g or 5g daily of 2′-fucosyllactose (2′-FL), a sugar found in human breast milk, or a placebo. While the primary endpoint—cytokine response—was not met, 2′-FL significantly increased gut Bifidobacterium, raised HDL cholesterol, fasting insulin, and the metabolic hormone FGF21. Participants whose Bifidobacterium levels responded to the supplement also showed improved visual memory and broader metabolic and proteomic changes. Those who lacked Bifidobacterium at baseline were less likely to respond. The findings suggest human milk oligosaccharides retain biological relevance well beyond infancy, offering a promising prebiotic strategy to support healthy aging.
Detailed Summary
Aging drives immunosenescence—a state of chronic low-grade inflammation combined with blunted immune responses—that underlies many age-related diseases including atherosclerosis, cancer, and neurodegeneration. Because the gut microbiome is a key regulator of both metabolism and immune function, and because it deteriorates with age, researchers hypothesized that microbiota-targeted dietary interventions might help reverse some of these changes. This study focused on 2′-fucosyllactose (2′-FL), the most abundant oligosaccharide in human breast milk and a well-established prebiotic that promotes Bifidobacterium growth in infants.
The RAMP Study (Rejuvenating the Aging Microbiota with Prebiotics; NCT03690999) was a randomized, double-blind, placebo-controlled trial enrolling 89 healthy older adults (mean age 67.3 years, range 60–84). Participants were assigned to high-dose 2′-FL (5 g/day, n=29), low-dose 2′-FL (1 g/day, n=30), or placebo (glucose, n=30) for 6 weeks, with a 4-week washout. Stool, blood, and urine samples were collected at five time points; cognitive assessments were administered at each visit. Multi-omics analyses included 16S rRNA gut microbiome profiling, serum metabolomics, proteomics, standard lipid panels, hormonal assays, and cytokine stimulation assays.
2′-FL was well tolerated with no adverse events. It was detectable in plasma (62% of high-dose participants) and urine (90% of high-dose), confirming systemic absorption. The pre-specified primary endpoint—change in ex vivo cytokine response—was not statistically significant. However, high-dose 2′-FL significantly increased relative abundance of gut Bifidobacterium, elevated HDL cholesterol, raised fasting insulin levels, and increased circulating FGF21, a hormone linked to metabolic health and longevity. These effects were largely absent in placebo recipients.
A particularly notable finding was the identification of Bifidobacterium 'responders'—participants whose gut Bifidobacterium increased substantially during intervention. Responders showed amplified metabolic benefits, broader proteomic and metabolomic shifts, and importantly, improved performance on a visual memory cognitive test compared to non-responders. Individuals who lacked detectable Bifidobacterium at baseline were disproportionately represented among non-responders, suggesting baseline microbiome composition predicts prebiotic efficacy. Urine and blood metabolomics confirmed systemic response to 2′-FL beyond the gut.
The study provides proof-of-concept that human milk oligosaccharides remain biologically active in older adults, acting through both microbiota-dependent (prebiotic) and potentially microbiota-independent pathways. The elevation of FGF21 and HDL, combined with cognitive improvements in responders, positions 2′-FL as a candidate longevity-supporting supplement. However, the 6-week duration limits conclusions about long-term effects, and the trial was underpowered for its primary immune endpoint. Future studies should stratify by baseline Bifidobacterium status to enrich for responders and examine longer intervention periods.
Key Findings
- 2′-FL supplementation significantly increased gut Bifidobacterium in older adults over 6 weeks.
- High-dose 2′-FL raised HDL cholesterol, fasting insulin, and the longevity-linked hormone FGF21.
- Bifidobacterium 'responders' showed improved visual memory performance on cognitive testing.
- Participants lacking baseline Bifidobacterium were significantly less likely to respond to 2′-FL.
- 2′-FL was detectable in plasma and urine, confirming systemic absorption beyond the gut.
Methodology
This was a 6-week randomized, double-blind, placebo-controlled trial in 89 healthy adults aged 60–84, with three arms (placebo, 1g/day 2′-FL, 5g/day 2′-FL) and a 4-week washout. Multi-omics analyses included gut microbiome profiling, serum metabolomics, proteomics, lipid panels, hormonal assays, and cytokine stimulation. Cognitive assessments and anthropometrics were collected at five time points.
Study Limitations
The primary immune endpoint (cytokine response) was not met, and the 6-week intervention is too short to assess long-term health outcomes. The cohort was predominantly white and highly educated, limiting generalizability. The study was not powered to stratify results by baseline Bifidobacterium status, and COVID-19 pandemic disruptions affected sample collection for roughly a third of participants.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.